MedX Health Corp. (V:MDX)
Business Focus: Advanced Medical Equipment & Technology (NEC)
| Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
| Company Contact | |
| Address: | 1495 Bonhill Road, Unit # 1 Mississauga MISSISSAUGA ON L5T 1M2 |
| Tel: | N/A |
| Website: | https://medxhealth.com |
| IR: | See website |
| Key People | ||
| Stephen Lockyer Acting Chief Executive Officer, Director | Christopher H. Freeman Acting Chief Financial Officer, Corporate Secretary | Michael Druhan President - Dermatological Services and Products |
| Business Overview |
| MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use technology utilizing light and its remittance to view suspicious moles and lesions up to two millimeters (mm) beneath in a pain-free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology. |
| Financial Overview |
| For the nine months ended 30 September 2023, Medx Health Corp revenues increased 31% to C$390K. Net loss increased 6% to C$4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest Exp-Net of Capitalized Interest increase of 84% to C$1.6M (expense), Other administrative expenses increase from C$90K to C$315K (expense). |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $28.50M as of Sep 30, 2023 |
| Annual revenue (TTM): | $0.60M as of Sep 30, 2023 |
| EBITDA (TTM): | -$3.33M as of Sep 30, 2023 |
| Net annual income (TTM): | -$5.36M as of Sep 30, 2023 |
| Free cash flow (TTM): | -$3.77M as of Sep 30, 2023 |
| Net Debt Last Fiscal Year: | $5.65M as of Sep 30, 2023 |
| Shares outstanding: | 261,956,603 as of Feb 9, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
